Flow-dependent regulation of endothelial toll-like receptor 2 expression through inhibition of SP1 activity

Circulation Research

Volumn 95, Issue 7, 2004, Pages 684-691

  Dunzendorfer, Stefan ^a   Lee, Hyun Ku ^a   Tobias, Peter S ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Endothelial cell; Innate immunity; Shear stress; TLR2; TLR4

Indexed keywords

CASEIN KINASE II; CYSTEINE DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; LIGAND; LIPOPOLYSACCHARIDE; LIPOPROTEIN; MACROPHAGE ACTIVATING FACTOR; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; PROTEIN LIP19; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LAMINAR FLOW; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; SHEAR STRESS;

ARTERIOSCLEROSIS; CARRIER PROTEINS; CASEIN KINASE II; CELLS, CULTURED; CORONARY VESSELS; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HEMORHEOLOGY; HUMANS; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; OLIGOPEPTIDES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; STRESS, MECHANICAL; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTORS; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4944262285     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000143900.19798.47     Document Type: Article

References (43)

1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
3. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999;34:1975-1981.
4. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218-1226.
5. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways, Nat Med. 2004;10:416-421.
6. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103: 773-778.
7. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282:2035-2042.
8. Asakura T, Karino T. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries. Circ Res. 1990;66: 1045-1066.
9. Gnasso A, Irace C, Carallo C, De Franceschi MS, Motti C, Mattioli PL, Pujia A. In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis. Stroke. 1997;28: 993-998.
10. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998; 18:842-851.
11. Caro CG, Fitz-Gerald JM, Schroter RC. Atheroma and arterial wall shear. Observation, correlation and proposal of a shear dependent mass transfer mechanism for atherogenesis. Proc R Soc Lond B Biol Sci. 1971;177: 109-159.
12. Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler Thromb Vasc Biol. 1995;15:2-10.
13. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135-145.
14. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol. 2003; 15:5-11.
15. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105:1158-1161.
16. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004;101:10679-10684.
17. Lee HK, Lee J, Tobias PS. Two lipoproteins extracted from Escherichia coli K-12 LCD25 lipopolysaccharide are the major components responsible for Toll-like receptor 2-mediated signaling. J Immunol. 2002; 168:4012-4017.
18. DePaola N, Davies PF, Pritchard WF, Jr., Florez L, Harbeck N, Polacek DC. Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitro. Proc Natl Acad Sci U S A. 1999;96:3154-3159.
19. Morigi M, Zoja C, Figliuzzi M, Foppolo M, Micheletti G, Bontempelli M, Saronni M, Remuzzi G, Remuzzi A. Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. Blood. 1995;85: 1696-1703.
20. Brooks AR, Lelkes PI, Rubanyi GM. Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow. Physiol Genomics. 2002;9:27-41.
21. Dunzendorfer S, Lee HK, Soldau K, Tobias PS. Toll-like receptor 4 functions intracellularly in human coronary artery endothelial cells: roles of LBP and sCD14 in mediating LPS responses. FASEB J. 2004;18: 1117-1119.
22. Kravchenko VV, Pan Z, Han J, Herbert JM, Ulevitch RJ, Ye RD. Platelet-activating factor induces NF-kappa B activation through a G protein-coupled pathway. J Biol Chem. 1995;270:14928-14934.
23. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 1987;51:1079-1090.
24. Haehnel V, Schwarzfischer L, Fenton MJ, Rehli M. Transcriptional regulation of the human toll-like receptor 2 gene in monocytes and macrophages. J Immunol. 2002;168:5629-5637.
25. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2′). FEBS Lett. 2001;496:44-48.
26. Yamawaki H, Lehoux S, Berk BC. Chronic physiological shear stress inhibits tumor necrosis factor-induced proinflammatory responses in rabbit aorta perfused ex vivo. Circulation. 2003;108:1619-1625.
27. Jackson SP, MacDonald JJ, Lees-Miller S, Tjian R. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell. 1990;63:155-165.
28. Fojas dB, Collins NK, Du P, Azizkhan-Clifford J, Mudryj M. Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J. 2001;20:5737-5747.
29. Rohlff C, Ahmad S, Borellini F, Lei J, Glazer RI. Modulation of transcription factor Sp1 by cAMP-dependent protein kinase. J Biol Chem. 1997;272:21137-21141.
30. Black AR, Jensen D, Lin SY, Azizkhan JC. Growth/cell cycle regulation of Sp1 phosphorylation. J Biol Chem. 1999;274:1207-1215.
31. Hagen G, Muller S, Beato M, Suske G. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J. 1994;13:3843-3851.
32. Suske G. The Sp-family of transcription factors. Gene. 1999;238: 291-300.
33. Armstrong SA, Barry DA, Leggett RW, Mueller CR. Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. J Biol Chem. 1997;272:13489-13495.
34. Sun JM, Chen HY, Moniwa M, Litchfield DW, Seto E, Davie JR. The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J Biol Chem. 2002;277:35783-35786.
35. Rafty LA, Santiago FS, Khachigian LM. NF1/X represses PDGF A-chain transcription by interacting with Sp1 and antagonizing Sp1 occupancy of the promoter. EMBO J. 2002;21:334-343.
36. Rafty LA, Khachigian LM. Sp1 phosphorylation regulates inducible expression of platelet-derived growth factor B-chain gene via atypical protein kinase C-zeta. Nucleic Acids Res. 2001;29:1027-1033.
37. Boekhoudt GH, Guo Z, Beresford GW, Boss JM. Communication between NF-kappa B and Sp1 controls histone acetylation within the proximal promoter of the monocyte chemoattractant protein 1 gene. J Immunol. 2003;170:4139-4147.
38. Neish AS, Khachigian LM, Park A, Baichwal VR, Collins T. Sp1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. J Biol Chem. 1995;270:28903-28909.
39. Horie S, Ishii H, Matsumoto F, Kusano M, Kizaki K, Matsuda J, Kazama M. Acceleration of thrombomodulin gene transcription by retinoic acid: retinoic acid receptors and Sp1 regulate the promoter activity through interactions with two different sequences in the 5′-flanking region of human gene. J Biol Chem. 2001;276:2440-2450.
40. Yipp BG, Andonegui G, Howlett CJ, Robbins SM, Hartung T, Ho M, Kubes P. Profound differences in leukocyte-endothelial cell responses to lipopolysaccharide versus lipoteichoic acid. J Immunol. 2002;168: 4650-4658.
41. Wang T, Lafuse WP, Zwilling BS. NFkappaB and Sp1 elements are necessary for maximal transcription of toll-like receptor 2 induced by Mycobacterium avium. J Immunol. 2001;167:6924-6932.
42. Musikacharoen T, Matsuguchi T, Kikuchi T, Yoshikai Y. NF-kappa B and STAT5 play important roles in the regulation of mouse toll-like receptor 2 gene expression. J Immunol. 2001;166:4516-4524.
43. Fan J, Frey RS, Malik AB. TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. J Clin Invest. 2003;112: 1234-1243.